Beximco Pharmaceuticals Limited
BXP.L · LSE
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | -0.48 | -80.33 | 0.19 |
| FCF Yield | 23.69% | 15.46% | 7.13% | 7.70% |
| EV / EBITDA | 2.92 | 3.34 | 5.70 | 7.04 |
| Quality | ||||
| ROIC | 10.56% | 8.41% | 8.28% | 10.92% |
| Gross Margin | 44.23% | 43.55% | 45.61% | 47.21% |
| Cash Conversion Ratio | 1.43 | 1.34 | 1.07 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.59% | 10.01% | 10.62% | 8.93% |
| Free Cash Flow Growth | 81.64% | 32.14% | -26.29% | 6.05% |
| Safety | ||||
| Net Debt / EBITDA | 0.49 | 1.01 | 1.36 | 0.94 |
| Interest Coverage | 7.48 | 5.61 | 6.89 | 7.75 |
| Efficiency | ||||
| Inventory Turnover | 1.90 | 1.65 | 1.63 | 1.99 |
| Cash Conversion Cycle | 170.79 | 226.54 | 228.65 | 206.36 |